series-c-plus
Stage
1
Investors
About
Biosergen is a biotech company developing novel antifungal drugs, with a lead candidate BSG005 (a genetically improved polyene macrolide) aimed at treating invasive fungal infections in immunocompromised patients. The drug was invented in collaboration with NTNU and SINTEF and has completed a Phase 1 study and ongoing proof-of-concept work.
Explore Biosergen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.